ETIHX: Eventide Healthcare & Life Sciences I

Welcome to MutualFunds.com. Please help us personalize your experience.

Select the one that best describes you

Your personalized experience is almost ready.

Join other Individual Investors receiving FREE personalized market updates and research. Join other Institutional Investors receiving FREE personalized market updates and research. Join other Financial Advisors receiving FREE personalized market updates and research.

Thank you!

Check your email and confirm your subscription to complete your personalized experience.

Thank you for your submission, we hope you enjoy your experience

ETIHX Eventide Healthcare & Life Sciences I

  • Fund
  • ETIHX
  • Price as of: Dec 04, 2019
  • $40.12
    + $0.27 + 0.68%

Profile

ETIHX - Profile

Vitals

  • YTD Return 48.9%
  • 3 Yr Annualized Return 23.4%
  • 5 Yr Annualized Return 15.8%
  • Net Assets $944 M
  • Holdings in Top 10 41.6%

52 WEEK LOW AND HIGH

$40.12
$24.45
$40.12

Expenses

OPERATING RELATED FEES

  • Expense Ratio 1.29%

SALES FEES

  • Front Load N/A
  • Deferred Load N/A

BROKERAGE FEES

  • Turnover 53.00%

TRADING FEES

  • Max Redemption Fee 1.00%

Min Investment

  • Standard (Taxable) $100,000
  • IRA $100,000

Fund Classification


Distributions

  • YTD Total Return 48.9%
  • 3 Yr Annualized Total Return 24.0%
  • 5 Yr Annualized Total Return 16.4%
  • Capital Gain Distribution Frequency Annually
  • Net Income Ratio -1.19%
DIVIDENDS
  • Dividend Yield 0.0%
  • Dividend Distribution Frequency Annually

Fund Details

  • Legal Name
    Eventide Healthcare & Life Sciences Fund
  • Fund Family Name
    Eventide Funds
  • Inception Date
    Dec 27, 2012
  • Shares Outstanding
    N/A
  • Share Class
    Inst
  • Currency
    USD
  • Domiciled Country
    United States
  • Manager
    Finny Kuruvilla

Fund Description

Under normal market conditions, the fund will invest at least 80% of its net assets (plus borrowings for investment purposes) in equity and equity-related securities of companies in the healthcare and life sciences sectors, including common stock, options, preferred stock and convertible debt. It may invest without limitation in securities of companies domiciled outside the United States either directly or through American Depositary Receipts ("ADRs"). The fund may invest in securities of companies of any market capitalization.


Get Updates About ETIHX

Sign up for Advisor Access to receive email updates about ETIHX competitors, news, CE accredited webcasts and more.

Please Enter Your Email
Please Select Your Advisor Type

Categories

Performance

ETIHX - Performance

Return Ranking - Trailing

Period ETIHX Return Category Return Low Category Return High Rank in Category (%)
YTD 48.9% 9.2% 48.9% 0.85%
1 Yr 25.3% -18.6% 25.8% 1.69%
3 Yr 23.4%* -12.2% 28.3% 1.80%
5 Yr 15.8%* -11.2% 15.8% 0.95%
10 Yr N/A* -1.9% 16.9% N/A

* Annualized

Return Ranking - Calendar

Period ETIHX Return Category Return Low Category Return High Rank in Category (%)
2018 -6.9% -25.3% 21.5% 42.34%
2017 43.9% -10.8% 43.9% 0.92%
2016 -16.0% -31.6% 6.9% 50.94%
2015 13.8% -20.4% 13.8% 0.97%
2014 29.3% -5.8% 31.5% 5.21%

Total Return Ranking - Trailing

Period ETIHX Return Category Return Low Category Return High Rank in Category (%)
YTD 48.9% 9.2% 48.9% 0.85%
1 Yr 25.3% -18.6% 33.9% 2.54%
3 Yr 24.0%* -12.2% 28.3% 2.70%
5 Yr 16.4%* -11.2% 17.8% 2.86%
10 Yr N/A* -1.9% 18.0% N/A

* Annualized

Total Return Ranking - Calendar

Period ETIHX Return Category Return Low Category Return High Rank in Category (%)
2018 -6.9% -25.3% 22.2% 50.45%
2017 45.8% -10.8% 45.8% 0.92%
2016 -16.0% -26.4% 8.7% 65.09%
2015 15.2% -16.6% 15.2% 0.97%
2014 29.3% -5.8% 36.7% 20.83%

NAV & Total Return History


Holdings

ETIHX - Holdings

Concentration Analysis

ETIHX Category Low Category High ETIHX % Rank
Net Assets 944 M 2.62 M 45.1 B 56.69%
Number of Holdings 62 26 388 77.95%
Net Assets in Top 10 450 M 857 K 17.4 B 50.39%
Weighting of Top 10 41.56% 20.8% 75.3% 40.16%

Top 10 Holdings

  1. Sarepta Therapeutics Inc 6.63%
  2. Ascendis Pharma A/S ADR 6.12%
  3. Sage Therapeutics Inc 5.49%
  4. Zogenix Inc 4.49%
  5. Blueprint Medicines Corp 4.02%
  6. Biohaven Pharmaceutical Holding Co Ltd 3.33%
  7. KalVista Pharmaceuticals Inc 3.07%
  8. MyoKardia Inc 2.87%
  9. GW Pharmaceuticals PLC ADR 2.78%
  10. Neurocrine Biosciences Inc 2.75%

Asset Allocation

Weighting Return Low Return High ETIHX % Rank
Stocks
94.10% 90.21% 103.54% 95.28%
Other
3.81% -27.41% 3.81% 0.79%
Cash
2.09% 0.00% 9.79% 36.22%
Preferred Stocks
0.00% 0.00% 1.43% 33.07%
Convertible Bonds
0.00% 0.00% 1.54% 23.62%
Bonds
0.00% 0.00% 20.60% 23.62%

Stock Sector Breakdown

Weighting Return Low Return High ETIHX % Rank
Healthcare
92.64% 56.60% 99.67% 85.04%
Industrials
1.45% 0.00% 2.40% 2.36%
Utilities
0.00% 0.00% 0.00% 15.75%
Technology
0.00% 0.00% 16.35% 61.42%
Real Estate
0.00% 0.00% 5.81% 22.83%
Financial Services
0.00% 0.00% 6.37% 36.22%
Energy
0.00% 0.00% 0.43% 19.69%
Communication Services
0.00% 0.00% 1.02% 16.54%
Consumer Defense
0.00% 0.00% 33.15% 28.35%
Consumer Cyclical
0.00% 0.00% 10.49% 25.98%
Basic Materials
0.00% 0.00% 1.66% 35.43%

Stock Geographic Breakdown

Weighting Return Low Return High ETIHX % Rank
US
83.42% 58.43% 99.93% 43.31%
Non US
10.68% 0.00% 39.77% 64.57%

Expenses

ETIHX - Expenses

Operational Fees

ETIHX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Expense Ratio 1.29% 0.10% 4.94% 47.01%
Management Fee 1.10% 0.09% 1.30% 90.55%
12b-1 Fee 0.00% 0.00% 1.00% 1.39%
Administrative Fee 0.10% 0.01% 0.40% 37.50%

Sales Fees

ETIHX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Front Load N/A 2.50% 5.75% N/A
Deferred Load N/A 1.00% 5.00% N/A

Trading Fees

ETIHX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Max Redemption Fee 1.00% 0.75% 2.00% 43.90%

Related Fees

Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.

ETIHX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Turnover 53.00% 0.00% 341.00% 71.19%

Distributions

ETIHX - Distributions

Dividend Yield Analysis

ETIHX Category Low Category High ETIHX % Rank
Dividend Yield 0.00% 0.00% 3.94% 33.07%

Dividend Distribution Analysis

ETIHX Category Low Category High Category Mod
Dividend Distribution Frequency Annually Annually Quarterly Annually

Net Income Ratio Analysis

ETIHX Category Low Category High ETIHX % Rank
Net Income Ratio -1.19% -2.24% 2.12% 91.45%

Capital Gain Distribution Analysis

ETIHX Category Low Category High Capital Mode
Capital Gain Distribution Frequency Annually Annually Semi-Annually Annually

Dividend Payout History

View More +

Fund Manager Analysis

ETIHX - Fund Manager Analysis

Managers

Finny Kuruvilla


Start Date

Tenure

Tenure Rank

Dec 27, 2012

6.85

6.9%

Finny Kuruvilla, M.D., Ph.D., has been primarily responsible for the day-to-day management of the Gilead Fund and Healthcare & Life Sciences Fund since inception. Dr. Kuruvilla has been the Managing Partner of the Adviser since its inception in 2008. Dr. Kuruvilla possesses a diverse background in quantitative methods, with applications focused on innovations in science, engineering, and medicine. He holds an MD from Harvard Medical School, a PhD in Chemistry and Chemical Biology from Harvard University, a master’s degree in Electrical Engineering and Computer Science from MIT, and a bachelor’s degree from Caltech in Chemistry. From 2005-2008, Dr. Kuruvilla was a clinical fellow at the Brigham and Women's Hospital and a postdoctoral scientist at MIT. As an avid proponent of values-based investing, Dr. Kuruvilla has established rigorous standards in seeking out the most ethical companies at the outset of the stock selection process. In addition to his role with the Adviser, Dr. Kuruvilla is a founder, financial sponsor, and Board Director of Sattler College, a four-year college in Boston, Massachusetts, opened in 2018. Dr. Kuruvilla also contributes to the college in a limited faculty role. From 2008-2016, Dr. Kuruvilla provided research services as an employee of Clarus Ventures, a healthcare and life sciences venture capital firm. From 2006-2008, Dr. Kuruvilla was a research fellow at the Broad Institute of Harvard and MIT.

Tenure Analysis

Category Low Category High Category Average Category Mode
0.34 22.14 9.7 19.51